Retrospective Case Series Analysis of Clinical Outcomes Associated with Management of Severe Community Acquired Pneumonia Cases due to K. pneumoniae with CSE-1034
Abstract
Background: In India, the rapid emergence of multi-drug resistance among community acquired pneumonia (CAP) causing pathogens contributes to the seriousness of these infections and is currently a major treatment-related issue. The objective of this case series was to determine the clinical efficacy of antibiotic adjuvant entity (CSE-1034: Ceftriaxone+Sulbactam+EDTA) in severe CAP cases. Methods: Severe CAP patients due to K. pneumoniae who were hospitalized and treated with CSE1034 as monotherapy or combination therapy were screened and further analyzed. CSE-1034 therapy was started in all these subjects based on culture sensitivity (C/s) profile and continued or discontinued depending on clinical response. Results: 25 K. pneumoniae culture-positive patients with mean age of 52 years were included in this case series. C/s profile has shown that pathogens isolated from all subjects were completely resistant to amikacin, cefazolin, ceftriaxone, pipericillin-tazobactam (pip-taz) and cefoperazone/sulbactam. Sensitivity pattern of CSE-1034 was 100% and meropenem was 85%. The C/s reports and clinical response to CSE-1034 were in concordance in 92% patients. 23/25 (92%) patients treated with CSE-1034 were cured with CSE-1034 monotherapy and 2/25 (8%) with CSE-1034+colistin combination therapy. Conclusion: From this case series, it can be presumed that CSE-1034 can serve as effective replacement to BL/BLI combinations and appears to be effective drug for treatment of severe CAP…
How strong is the evidence?
Evidence Hub reads this as a case series, done in people. Its evidence level is 5 of 5 (Very low · case / narrative / animal / in vitro / in silico). Case reports, narrative reviews, and animal, cell or computer-model studies give the weakest evidence for human health.
Read the paper
Related studies
- Penicillins for Treatment of Pneumococcal Pneumonia: Does In Vitro Resistance Really Matter?
- Thiophenes—Naturally Occurring Plant Metabolites: Biological Activities and In Silico Evaluation of Their Potential as Cathepsin D Inhibitors
- Inhalable Mannosylated Rifampicin–Curcumin Co-Loaded Nanomicelles with Enhanced In Vitro Antimicrobial Efficacy for an Optimized Pulmonary Tuberculosis Therapy
- Development and validation of microbial bioassay for quantification of Levofloxacin in pharmaceutical preparations
- GC-MS Analysis and Biomedical Therapy of Oil from n-Hexane Fraction of Scutellaria edelbergii Rech. f.: In Vitro, In Vivo, and In Silico Approach
- Propranolol, chlorpromazine and diclofenac restore susceptibility of extensively drug-resistant (XDR)-Acinetobacter baumannii to fluoroquinolones
Go deeper in Evidence Hub
Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.